[Skip to Navigation]
December 13, 2006

Preimplantation Genetic Diagnosis for Cancer Syndromes: A New Challenge for Preventive Medicine

Author Affiliations

Author Affiliations: Clinical Genetics Service, Department of Medicine (Dr Offit) and Department of Psychiatry (Dr Hurley), Memorial Sloan-Kettering Cancer Center, New York, NY; and Department of Human Genetics, Hadassah-Hebrew University Hospital, Jerusalem, Israel (Dr Sagi).

JAMA. 2006;296(22):2727-2730. doi:10.1001/jama.296.22.2727

Over the next decade, health care professionals may increasingly be involved in discussions of reproductive options when providing preventive medicine guidance to patients and their families affected by hereditary cancer syndromes. Preimplantation genetic diagnosis (PGD) is one means of assisted reproductive technology (ART) wherein embryos that do not inherit a familial mutation are selected for implantation and gestation. Recently, we documented 55 published reports as well as unpublished experiences using ART for 22 common predisposition syndromes, including hereditary breast, ovarian, and colon cancer.1